These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein compositional abnormalities in type I diabetes: effect of improved glycaemic control. Pérez A; Caixàs A; Carreras G; Mauricio D; Pou JM; Serrat J; Gómez-Gerique J; de Leiva A Diabetes Res Clin Pract; 1997 May; 36(2):83-90. PubMed ID: 9229192 [TBL] [Abstract][Full Text] [Related]
7. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975 [TBL] [Abstract][Full Text] [Related]
8. [Value of the analysis of lipoproteins after myocardial infarction]. Dewailly P; Mellin D; Moulin S; Rouget JP; Sezille G; Jaillard J Presse Med; 1983 Jul 9-16; 12(29):1807-10. PubMed ID: 6224195 [TBL] [Abstract][Full Text] [Related]
9. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients. Ybarra J; James RW; Makoundou V; Bioletto S; Golay A Diabetes Metab; 2001 Dec; 27(6):701-8. PubMed ID: 11852380 [TBL] [Abstract][Full Text] [Related]
10. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160 [TBL] [Abstract][Full Text] [Related]
11. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Steiner G; Schwartz L; Shumak S; Poapst M Circulation; 1987 Jan; 75(1):124-30. PubMed ID: 3791598 [TBL] [Abstract][Full Text] [Related]
12. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Taskinen MR; Packard CJ; Shepherd J Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727 [TBL] [Abstract][Full Text] [Related]
14. Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients. A longitudinal study. Lopes-Virella MF; Wohltmann HJ; Mayfield RK; Loadholt CB; Colwell JA Diabetes; 1983 Jan; 32(1):20-5. PubMed ID: 6336700 [No Abstract] [Full Text] [Related]
15. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863 [TBL] [Abstract][Full Text] [Related]
16. Influence of artificial fat emulsions on the composition of serum lipoproteins in humans. Hailer S; Wolfram G Am J Clin Nutr; 1986 Feb; 43(2):225-33. PubMed ID: 3080868 [TBL] [Abstract][Full Text] [Related]
17. [Reduction of lipoproteins with apoAI but without apoAII (LpAI) in non-insulin-dependent diabetic patients]. Barkia A; Zouari N; Khrouf W; Ellouz F; Zouaghi H Ann Biol Clin (Paris); 1996; 54(2):83-6. PubMed ID: 8763631 [TBL] [Abstract][Full Text] [Related]